Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asfar S Azmi

Showing results (41-50 of 154) with videos related to

Pageof 16
Sort By:
Molecular Cancer Therapeutics|November 3, 2010
Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinationsAsfar S Azmi, Zhiwei Wang, Philip A Philip, et al.
Current Drug Targets|July 10, 2013
Nuclear export mediated regulation of microRNAs: potential target for drug interventionIrfana Muqbil, Bin Bao, Abdul Badi Abou-Samra, et al.
Cancer Treatment Reviews|October 29, 2021
KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyondMisako Nagasaka, Bindu Potugari, Alexis Nguyen, et al.
Current Pharmaceutical Design|February 1, 2014
Regulation of KRAS-PAK4 axis by microRNAs in cancerZeshan S Choudhry, Vraj Tripathi, Mike Sutton, et al.
Epigenomics|December 1, 2011
Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspectiveAsfar S Azmi, Frances W J Beck, Bin Bao, et al.
Cancers|August 27, 2021
Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAsYiwei Li, Mohammed Najeeb Al Hallak, Philip A Philip, et al.
Technology in Cancer Research & Treatment|August 18, 2020
Gastric Cancer Heterogeneity and Clinical OutcomesRachel E Sexton, Mohammed Najeeb Al Hallak, Md Hafiz Uddin, et al.
Expert Opinion on Therapeutic Targets|April 30, 2010
PAR-4 as a possible new target for pancreatic cancer therapyAsfar S Azmi, Philip A Philip, Syed F Zafar, et al.
Cancers|August 7, 2019
DNA-Methylation-Caused Downregulation of <i>miR-30</i> Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal AdenocarcinomaAsfar S Azmi, Yiwei Li, Amro Aboukameel, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 10, 2010
Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistanceZhiwei Wang, Yiwei Li, Aamir Ahmad, et al.
Pageof 16

Showing results (41-50 of 154) with videos related to

Sort By:
Pageof 16
Molecular Cancer Therapeutics|November 3, 2010
Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinationsAsfar S Azmi, Zhiwei Wang, Philip A Philip, et al.
Current Drug Targets|July 10, 2013
Nuclear export mediated regulation of microRNAs: potential target for drug interventionIrfana Muqbil, Bin Bao, Abdul Badi Abou-Samra, et al.
Cancer Treatment Reviews|October 29, 2021
KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyondMisako Nagasaka, Bindu Potugari, Alexis Nguyen, et al.
Current Pharmaceutical Design|February 1, 2014
Regulation of KRAS-PAK4 axis by microRNAs in cancerZeshan S Choudhry, Vraj Tripathi, Mike Sutton, et al.
Epigenomics|December 1, 2011
Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspectiveAsfar S Azmi, Frances W J Beck, Bin Bao, et al.
Cancers|August 27, 2021
Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAsYiwei Li, Mohammed Najeeb Al Hallak, Philip A Philip, et al.
Technology in Cancer Research & Treatment|August 18, 2020
Gastric Cancer Heterogeneity and Clinical OutcomesRachel E Sexton, Mohammed Najeeb Al Hallak, Md Hafiz Uddin, et al.
Expert Opinion on Therapeutic Targets|April 30, 2010
PAR-4 as a possible new target for pancreatic cancer therapyAsfar S Azmi, Philip A Philip, Syed F Zafar, et al.
Cancers|August 7, 2019
DNA-Methylation-Caused Downregulation of <i>miR-30</i> Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal AdenocarcinomaAsfar S Azmi, Yiwei Li, Amro Aboukameel, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 10, 2010
Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistanceZhiwei Wang, Yiwei Li, Aamir Ahmad, et al.
Pageof 16